US Edition
Anthropic Adds Novartis CEO Vas Narasimhan to Its Board
The appointment comes as Anthropic expands into healthcare and weighs an initial public offering, with the company recently buying biotech start-up Coefficient Bio for $400 million.
- On Tuesday, Anthropic added Novartis CEO Vas Narasimhan to its board of directors, making him the first pharmaceutical executive to join the AI startup's governing body.
- The Anthropic Long-Term Benefit Trust, an independent body designed to protect the company's mission from short-term commercial pressures, appointed Narasimhan to oversee long-term direction.
- According to the Wall Street Journal, Narasimhan's appointment supports Anthropic's planned healthcare business expansion and a potential initial public offering expected as early as 2026.
- Former Microsoft executive Chris Liddell joined the board in February, bringing experience from his White House service during Donald Trump's first presidency.
- Anthropic recently acquired biotech startup Coefficient Bio for $400 million as pharmaceutical companies race to secure advanced AI capacity for scientific challenges.
20 Articles
20 Articles
Antropic Recruits Novartis CEO to Board to Strengthen Healthcare Expansion and IPO Foundation AI company Antropic is accelerating the expansion of its healthcare business and preparations for an initial public offering (IPO) by recruiting the CEO of Novartis to its board of directors. On the 14th (local time), Antropic... Long-term Benefit Trust (LTBT), an independent entity...
Times of India
The Economic TimesAnthropic appoints Indian-origin Novartis CEO Vas Narasimhan to its board
Anthropic’s Long-Term Benefit Trust is an independent governance body, designed to insulate key decisions as it scales its frontier AI systems. Narasimhan brings deep experience at the intersection of medicine, regulation, and global health. As the chief executive of Novartis, he has overseen the development and approval of more than 35 novel medicines.
Coverage Details
Bias Distribution
- 45% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
